Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 225

1.

Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer.

van Veggel B, Madeira R Santos JFV, Hashemi SMS, Paats MS, Monkhorst K, Heideman DAM, Groves M, Radonic T, Smit EF, Schuuring E, van der Wekken AJ, de Langen AJ.

Lung Cancer. 2019 Dec 20;141:9-13. doi: 10.1016/j.lungcan.2019.12.013. [Epub ahead of print]

PMID:
31926441
2.

Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition.

Boers J, Venema CM, de Vries EFJ, Glaudemans AWJM, Kwee TC, Schuuring E, Martens JWM, Elias SG, Hospers GAP, Schröder CP.

Eur J Cancer. 2019 Dec 28;126:11-20. doi: 10.1016/j.ejca.2019.10.024. [Epub ahead of print]

PMID:
31891878
3.

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.

Thunnissen E, Lissenberg-Witte BI, van den Heuvel MM, Monkhorst K, Skov BG, Sørensen JB, Mellemgaard A, Dingemans AMC, Speel EJM, de Langen AJ, Hashemi SMS, Bahce I, van der Drift MA, Looijen-Salamon MG, Gosney J, Postmus PE, Samii SMS, Duplaquet F, Weynand B, Durando X, Penault-Llorca F, Finn S, Grady AO, Oz B, Akyurek N, Buettner R, Wolf J, Bubendorf L, Duin S, Marondel I, Heukamp LC, Timens W, Schuuring EMD, Pauwels P, Smit EF.

Lung Cancer. 2019 Dec;138:13-18. doi: 10.1016/j.lungcan.2019.09.023. Epub 2019 Oct 3.

PMID:
31630043
4.

Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows.

Lampignano R, Neumann MHD, Weber S, Kloten V, Herdean A, Voss T, Groelz D, Babayan A, Tibbesma M, Schlumpberger M, Chemi F, Rothwell DG, Wikman H, Galizzi JP, Bergheim IR, Russnes H, Mussolin B, Bonin S, Voigt C, Musa H, Pinzani P, Lianidou E, Brady G, Speicher MR, Pantel K, Betsou F, Schuuring E, Kubista M, Ammerlaan W, Sprenger-Haussels M, Schlange T, Heitzer E; Innovative Medicines Initiative CANCER-ID Consortium.

Clin Chem. 2019 Oct 18. pii: clinchem.2019.306837. doi: 10.1373/clinchem.2019.306837. [Epub ahead of print]

PMID:
31628139
5.

Standardised Ki-67 proliferation index assessment in early-stage laryngeal squamous cell carcinoma in relation to local control and survival after primary radiotherapy.

Kop E, de Bock GH, Noordhuis MG, Slagter-Menkema L, van der Laan BFAM, Langendijk JA, Schuuring E, van der Vegt B.

Clin Otolaryngol. 2020 Jan;45(1):12-20. doi: 10.1111/coa.13449. Epub 2019 Nov 5.

PMID:
31561282
6.

Variation in nomenclature of somatic variants for selection of oncological therapies: Can we reach a consensus soon?

Keppens C, Tack V, Dufraing K, Rouleau E, Ligtenberg MJL, Schuuring E, Dequeker EMC.

Hum Mutat. 2020 Jan;41(1):7-16. doi: 10.1002/humu.23926. Epub 2019 Oct 14.

PMID:
31553104
7.

PTEN Is Associated With Worse Local Control in Early Stage Supraglottic Laryngeal Cancer Treated With Radiotherapy.

Bruine de Bruin L, Wachters JE, Schrijvers ML, Slagter-Menkema L, Mastik MF, Langendijk JA, van der Wal JE, Schuuring E, van der Laan BFAM.

Laryngoscope Investig Otolaryngol. 2019 Jun 12;4(4):399-404. doi: 10.1002/lio2.272. eCollection 2019 Aug.

8.

Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors.

Tamminga M, de Wit S, Hiltermann TJN, Timens W, Schuuring E, Terstappen LWMM, Groen HJM.

J Immunother Cancer. 2019 Jul 10;7(1):173. doi: 10.1186/s40425-019-0649-2.

9.

IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing.

Deans ZC, Butler R, Cheetham M, Dequeker EMC, Fairley JA, Fenizia F, Hall JA, Keppens C, Normanno N, Schuuring E, Patton SJ.

Virchows Arch. 2019 Jun;474(6):681-689. doi: 10.1007/s00428-019-02571-3. Epub 2019 Apr 26.

10.

Addition of tumour infiltration depth and extranodal extension improves the prognostic value of the pathological TNM classification for early-stage oral squamous cell carcinoma.

Boeve K, Melchers LJ, Schuuring E, Roodenburg JL, Halmos GB, van Dijk BA, van der Vegt B, Witjes MJ.

Histopathology. 2019 Sep;75(3):329-337. doi: 10.1111/his.13886. Epub 2019 Jul 29.

11.

Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics.

Eijkelenboom A, Tops BBJ, van den Berg A, van den Brule AJC, Dinjens WNM, Dubbink HJ, Ter Elst A, Geurts-Giele WRR, Groenen PJTA, Groenendijk FH, Heideman DAM, Huibers MMH, Huijsmans CJJ, Jeuken JWM, van Kempen LC, Korpershoek E, Kroeze LI, de Leng WWJ, van Noesel CJM, Speel EM, Vogel MJ, van Wezel T, Nederlof PM, Schuuring E, Ligtenberg MJL.

Virchows Arch. 2019 Jun;474(6):673-680. doi: 10.1007/s00428-019-02555-3. Epub 2019 Mar 19.

12.

Diagnosis and Treatment Monitoring of a Patient with Gastrointestinal Stromal Tumor by Next-Generation Sequencing and Droplet Digital Polymerase Chain Reaction Assay of a PDGFRA Mutation in Plasma-Derived Cell-Free Tumor DNA.

Boonstra PA, Ter Elst A, Tibbesma M, Gietema JA, Schuuring E, Reyners AKL.

Oncologist. 2019 Jun;24(6):e387-e390. doi: 10.1634/theoncologist.2018-0460. Epub 2019 Jan 22.

13.

Single tube liquid biopsy for advanced non-small cell lung cancer.

de Wit S, Rossi E, Weber S, Tamminga M, Manicone M, Swennenhuis JF, Groothuis-Oudshoorn CGM, Vidotto R, Facchinetti A, Zeune LL, Schuuring E, Zamarchi R, Hiltermann TJN, Speicher MR, Heitzer E, Terstappen LWMM, Groen HJM.

Int J Cancer. 2019 Jun 15;144(12):3127-3137. doi: 10.1002/ijc.32056. Epub 2019 Jan 28.

PMID:
30536653
14.

KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC.

Niemantsverdriet M, Schuuring E, Elst AT, van der Wekken AJ, van Kempen LC, van den Berg A, Groen HJM.

J Thorac Oncol. 2018 Dec;13(12):e249-e251. doi: 10.1016/j.jtho.2018.07.103. No abstract available.

15.

DNA methylation markers as a triage test for identification of cervical lesions in a high risk human papillomavirus positive screening cohort.

van Leeuwen RW, Oštrbenk A, Poljak M, van der Zee AGJ, Schuuring E, Wisman GBA.

Int J Cancer. 2019 Feb 15;144(4):746-754. doi: 10.1002/ijc.31897. Epub 2018 Oct 31.

16.

Accreditation, setting and experience as indicators to assure quality in oncology biomarker testing laboratories.

Tack V, Schuuring E, Keppens C, Hart N', Pauwels P, van Krieken H, Dequeker EMC.

Br J Cancer. 2018 Aug;119(5):605-614. doi: 10.1038/s41416-018-0204-9. Epub 2018 Aug 24.

17.

International pilot external quality assessment scheme for analysis and reporting of circulating tumour DNA.

Keppens C, Dequeker EMC, Patton SJ, Normanno N, Fenizia F, Butler R, Cheetham M, Fairley JA, Williams H, Hall JA, Schuuring E, Deans ZC; IQN Path ASBL.

BMC Cancer. 2018 Aug 9;18(1):804. doi: 10.1186/s12885-018-4694-x.

18.

Host-cell DNA methylation patterns during high-risk HPV-induced carcinogenesis reveal a heterogeneous nature of cervical pre-cancer.

Verlaat W, Van Leeuwen RW, Novianti PW, Schuuring E, Meijer CJLM, Van Der Zee AGJ, Snijders PJF, Heideman DAM, Steenbergen RDM, Wisman GBA.

Epigenetics. 2018;13(7):769-778. doi: 10.1080/15592294.2018.1507197. Epub 2018 Aug 24.

19.

Describing the Reportable Range Is Important for Reliable Treatment Decisions: A Multiple Laboratory Study for Molecular Tumor Profiling Using Next-Generation Sequencing.

Tack V, Spans L, Schuuring E, Keppens C, Zwaenepoel K, Pauwels P, Van Houdt J, Dequeker EMC.

J Mol Diagn. 2018 Nov;20(6):743-753. doi: 10.1016/j.jmoldx.2018.06.006. Epub 2018 Jul 26.

20.

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification.

Meedendorp AD, Ter Elst A, 't Hart NA, Groen HJM, Schuuring E, van der Wekken AJ.

Front Oncol. 2018 May 22;8:176. doi: 10.3389/fonc.2018.00176. eCollection 2018.

21.

A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer.

Keppens C, Tack V, Hart N', Tembuyser L, Ryska A, Pauwels P, Zwaenepoel K, Schuuring E, Cabillic F, Tornillo L, Warth A, Weichert W, Dequeker E; EQA assessors expert group.

Oncotarget. 2018 Apr 17;9(29):20524-20538. doi: 10.18632/oncotarget.24980. eCollection 2018 Apr 17.

22.

Data-Driven prioritisation of antibody-drug conjugate targets in head and neck squamous cell carcinoma.

Hanemaaijer SH, van Gijn SE, Oosting SF, Plaat BEC, Moek KL, Schuuring EM, van der Laan BFAM, Roodenburg JLN, van Vugt MATM, van der Vegt B, Fehrmann RSN.

Oral Oncol. 2018 May;80:33-39. doi: 10.1016/j.oraloncology.2018.03.005. Epub 2018 Mar 27.

PMID:
29706186
23.

Detection of EGFR Variants in Plasma: A Multilaboratory Comparison of a Real-Time PCR EGFR Mutation Test in Europe.

Keppens C, Palma JF, Das PM, Scudder S, Wen W, Normanno N, van Krieken JH, Sacco A, Fenizia F, Gonzalez de Castro D, Hönigschnabl S, Kern I, Lopez-Rios F, Lozano MD, Marchetti A, Halfon P, Schuuring E, Setinek U, Sorensen B, Taniere P, Tiemann M, Vosmikova H, Dequeker EMC.

J Mol Diagn. 2018 Jul;20(4):483-494. doi: 10.1016/j.jmoldx.2018.03.006. Epub 2018 Apr 26.

24.

High sensitivity and negative predictive value of sentinel lymph node biopsy in a retrospective early stage oral cavity cancer cohort in the Northern Netherlands.

Boeve K, Schepman KP, Schuuring E, Roodenburg JLN, Halmos GB, van Dijk BAC, Boorsma RAC, de Visscher JGAM, Brouwers AH, van der Vegt B, Witjes MJH.

Clin Otolaryngol. 2018 Mar 25. doi: 10.1111/coa.13107. [Epub ahead of print]

PMID:
29575685
25.

A single digital droplet PCR assay to detect multiple KIT exon 11 mutations in tumor and plasma from patients with gastrointestinal stromal tumors.

Boonstra PA, Ter Elst A, Tibbesma M, Bosman LJ, Mathijssen R, Atrafi F, van Coevorden F, Steeghs N, Farag S, Gelderblom H, van der Graaf WTA, Desar IME, Maier J, Overbosch J, Suurmeijer AJH, Gietema J, Schuuring E, Reyners AKL.

Oncotarget. 2018 Feb 14;9(17):13870-13883. doi: 10.18632/oncotarget.24493. eCollection 2018 Mar 2.

26.

Viable tumor in salvage neck dissections in head and neck cancer: Relation with initial treatment, change of lymph node size and human papillomavirus.

van den Bovenkamp K, Dorgelo B, Noordhuis MG, van der Laan BFAM, van der Vegt B, Bijl HP, Roodenburg JL, van Dijk BAC, Oosting SF, Schuuring EMD, Langendijk JA, Halmos GB, Plaat BEC.

Oral Oncol. 2018 Feb;77:131-136. doi: 10.1016/j.oraloncology.2017.12.017. Epub 2018 Jan 8.

PMID:
29362119
27.

Tyrosine kinase inhibitor sensitive PDGFRΑ mutations in GIST: Two cases and review of the literature.

Boonstra PA, Gietema JA, Suurmeijer AJH, Groves MR, de Assis Batista F, Schuuring E, Reyners AKL.

Oncotarget. 2017 Nov 26;8(65):109836-109847. doi: 10.18632/oncotarget.22663. eCollection 2017 Dec 12.

28.

Mutations in EMT-Related Genes in ALK Positive Crizotinib Resistant Non-Small Cell Lung Cancers.

Wei J, van der Wekken AJ, Saber A, Terpstra MM, Schuuring E, Timens W, Hiltermann TJN, Groen HJM, van den Berg A, Kok K.

Cancers (Basel). 2018 Jan 4;10(1). pii: E10. doi: 10.3390/cancers10010010.

29.

Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.

Bisschop C, Ter Elst A, Bosman LJ, Platteel I, Jalving M, van den Berg A, Diepstra A, van Hemel B, Diercks GFH, Hospers GAP, Schuuring E.

Melanoma Res. 2018 Apr;28(2):96-104. doi: 10.1097/CMR.0000000000000421.

30.

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.

van der Wekken AJ, Kuiper JL, Saber A, Terpstra MM, Wei J, Hiltermann TJN, Thunnissen E, Heideman DAM, Timens W, Schuuring E, Kok K, Smit EF, van den Berg A, Groen HJM.

PLoS One. 2017 Aug 30;12(8):e0182885. doi: 10.1371/journal.pone.0182885. eCollection 2017.

31.

Review of the implementation of plasma ctDNA testing on behalf of IQN Path ASBL: a perspective from an EQA providers' survey.

Deans ZC, Williams H, Dequeker EMC, Keppens C, Normanno N, Schuuring E, Patton SJ, Cheetham M, Butler R, Hall JA; IQN Path ASBL.

Virchows Arch. 2017 Dec;471(6):809-813. doi: 10.1007/s00428-017-2222-z. Epub 2017 Aug 25. No abstract available.

32.

Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer.

Tomar T, Alkema NG, Schreuder L, Meersma GJ, de Meyer T, van Criekinge W, Klip HG, Fiegl H, van Nieuwenhuysen E, Vergote I, Widschwendter M, Schuuring E, van der Zee AGJ, de Jong S, Wisman GBA.

BMC Med. 2017 Jun 23;15(1):116. doi: 10.1186/s12916-017-0870-0.

33.

Phosphorylated FADD is not prognostic for local control in T1-T2 supraglottic laryngeal carcinoma treated with radiotherapy.

Wachters JE, Schrijvers ML, Slagter-Menkema L, Mastik M, Langendijk JA, de Bock GH, Roodenburg JL, van der Laan BFAM, van der Wal JE, Schuuring E.

Laryngoscope. 2017 Sep;127(9):E301-E307. doi: 10.1002/lary.26563. Epub 2017 Mar 17.

PMID:
28304089
34.

Dichotomous ALK-IHC Is a Better Predictor for ALK Inhibition Outcome than Traditional ALK-FISH in Advanced Non-Small Cell Lung Cancer.

van der Wekken AJ, Pelgrim R, 't Hart N, Werner N, Mastik MF, Hendriks L, van der Heijden EHFM, Looijen-Salamon M, de Langen AJ, Staal-van den Brekel J, Riemersma S, van den Borne BE, Speel EJM, Dingemans AC, Hiltermann TJN, van den Berg A, Timens W, Schuuring E, Groen HJM.

Clin Cancer Res. 2017 Aug 1;23(15):4251-4258. doi: 10.1158/1078-0432.CCR-16-1631. Epub 2017 Feb 9.

35.

Lymphatic drainage patterns of oral maxillary tumors: Approachable locations of sentinel lymph nodes mainly at the cervical neck level.

Boeve K, Schepman KP, Vegt BV, Schuuring E, Roodenburg JL, Brouwers AH, Witjes MJ.

Head Neck. 2017 Mar;39(3):486-491. doi: 10.1002/hed.24628. Epub 2016 Dec 22.

PMID:
28006085
36.

Genome-wide methylome analysis using MethylCap-seq uncovers 4 hypermethylated markers with high sensitivity for both adeno- and squamous-cell cervical carcinoma.

Wang R, van Leeuwen RW, Boers A, Klip HG, de Meyer T, Steenbergen RD, van Criekinge W, van der Zee AG, Schuuring E, Wisman GB.

Oncotarget. 2016 Dec 6;7(49):80735-80750. doi: 10.18632/oncotarget.12598.

37.

Integration of next-generation sequencing in clinical diagnostic molecular pathology laboratories for analysis of solid tumours; an expert opinion on behalf of IQN Path ASBL.

Deans ZC, Costa JL, Cree I, Dequeker E, Edsjö A, Henderson S, Hummel M, Ligtenberg MJ, Loddo M, Machado JC, Marchetti A, Marquis K, Mason J, Normanno N, Rouleau E, Schuuring E, Snelson KM, Thunnissen E, Tops B, Williams G, van Krieken H, Hall JA; IQN Path ASBL.

Virchows Arch. 2017 Jan;470(1):5-20. doi: 10.1007/s00428-016-2025-7. Epub 2016 Sep 27. Review.

38.

Amplification and protein overexpression of cyclin D1: Predictor of occult nodal metastasis in early oral cancer.

Noorlag R, Boeve K, Witjes MJ, Koole R, Peeters TL, Schuuring E, Willems SM, van Es RJ.

Head Neck. 2017 Feb;39(2):326-333. doi: 10.1002/hed.24584. Epub 2016 Sep 21.

PMID:
27653309
39.

RAB25 expression is epigenetically downregulated in oral and oropharyngeal squamous cell carcinoma with lymph node metastasis.

Clausen MJ, Melchers LJ, Mastik MF, Slagter-Menkema L, Groen HJ, Laan BF, van Criekinge W, de Meyer T, Denil S, van der Vegt B, Wisman GB, Roodenburg JL, Schuuring E.

Epigenetics. 2016 Sep;11(9):653-663. Epub 2016 Jul 5.

40.

FGFR Family Members Protein Expression as Prognostic Markers in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma.

Koole K, Clausen MJ, van Es RJ, van Kempen PM, Melchers LJ, Koole R, Langendijk JA, van Diest PJ, Roodenburg JL, Schuuring E, Willems SM.

Mol Diagn Ther. 2016 Aug;20(4):363-74. doi: 10.1007/s40291-016-0204-5.

41.

Immunological response to quadrivalent HPV vaccine in treatment of recurrent respiratory papillomatosis.

Tjon Pian Gi RE, San Giorgi MR, Pawlita M, Michel A, van Hemel BM, Schuuring EM, van den Heuvel ER, van der Laan BF, Dikkers FG.

Eur Arch Otorhinolaryngol. 2016 Oct;273(10):3231-6. doi: 10.1007/s00405-016-4085-3. Epub 2016 May 17.

42.

Genomic Aberrations in Crizotinib Resistant Lung Adenocarcinoma Samples Identified by Transcriptome Sequencing.

Saber A, van der Wekken AJ, Kok K, Terpstra MM, Bosman LJ, Mastik MF, Timens W, Schuuring E, Hiltermann TJ, Groen HJ, van den Berg A.

PLoS One. 2016 Apr 5;11(4):e0153065. doi: 10.1371/journal.pone.0153065. eCollection 2016.

43.

Chronic Obstructive Pulmonary Disease Is Not Associated with KRAS Mutations in Non-Small Cell Lung Cancer.

Saber A, van der Wekken AJ, Kerner GS, van den Berge M, Timens W, Schuuring E, ter Elst A, van den Berg A, Hiltermann TJ, Groen HJ.

PLoS One. 2016 Mar 23;11(3):e0152317. doi: 10.1371/journal.pone.0152317. eCollection 2016.

44.

Discovery of new methylation markers to improve screening for cervical intraepithelial neoplasia grade 2/3.

Boers A, Wang R, van Leeuwen RW, Klip HG, de Bock GH, Hollema H, van Criekinge W, de Meyer T, Denil S, van der Zee AGJ, Schuuring E, Wisman GBA.

Clin Epigenetics. 2016 Mar 9;8:29. doi: 10.1186/s13148-016-0196-3. eCollection 2016.

45.

Re-expression of Selected Epigenetically Silenced Candidate Tumor Suppressor Genes in Cervical Cancer by TET2-directed Demethylation.

Huisman C, van der Wijst MG, Schokker M, Blancafort P, Terpstra MM, Kok K, van der Zee AG, Schuuring E, Wisman GB, Rots MG.

Mol Ther. 2016 Mar;24(3):536-47. doi: 10.1038/mt.2015.226. Epub 2015 Dec 21.

46.

Identification and validation of WISP1 as an epigenetic regulator of metastasis in oral squamous cell carcinoma.

Clausen MJ, Melchers LJ, Mastik MF, Slagter-Menkema L, Groen HJ, van der Laan BF, van Criekinge W, de Meyer T, Denil S, Wisman GB, Roodenburg JL, Schuuring E.

Genes Chromosomes Cancer. 2016 Jan;55(1):45-59. doi: 10.1002/gcc.22310. Epub 2015 Sep 22.

PMID:
26391330
47.

Assessment of hypoxic subvolumes in laryngeal cancer with (18)F-fluoroazomycinarabinoside ((18)F-FAZA)-PET/CT scanning and immunohistochemistry.

Bruine de Bruin L, Bollineni VR, Wachters JE, Schuuring E, van Hemel BM, van der Wal JE, Slagter-Menkema L, de Bock GH, Steenbakkers RJ, Langendijk JA, Pruim J, van der Laan BF, Halmos GB.

Radiother Oncol. 2015 Oct;117(1):106-12. doi: 10.1016/j.radonc.2015.07.012. Epub 2015 Aug 3.

PMID:
26250803
48.

Identification of methylation markers for the prediction of nodal metastasis in oral and oropharyngeal squamous cell carcinoma.

Melchers LJ, Clausen MJ, Mastik MF, Slagter-Menkema L, van der Wal JE, Wisman GB, Roodenburg JL, Schuuring E.

Epigenetics. 2015;10(9):850-60. doi: 10.1080/15592294.2015.1075689.

49.

Nationwide prevalence of human papillomavirus infection and viral genotype distribution in 37 cities in China.

Wang R, Guo XL, Wisman GB, Schuuring E, Wang WF, Zeng ZY, Zhu H, Wu SW.

BMC Infect Dis. 2015 Jul 4;15:257. doi: 10.1186/s12879-015-0998-5.

50.

Erratum to: Quality assessment of estrogen receptor and progesterone receptor testing in breast cancer using a tissue microarray-based approach.

Dekker TJ, ter Borg S, Hooijer GK, Meijer SL, Wesseling J, Boers JE, Schuuring E, Bart J, van Gorp J, Bult P, Riemersma SA, van Deurzen CH, Sleddens HF, Mesker WE, Kroep JR, Smit VT, van de Vijver MJ.

Breast Cancer Res Treat. 2015 Jul;152(2):253. doi: 10.1007/s10549-015-3478-0. No abstract available.

Supplemental Content

Loading ...
Support Center